Cassava Sciences, Moderna and Sorrento Therapeutics All Have News

News from Cassava Sciences, Moderna and Sorrento Therapeutics 
Cassava Sciences 
Cassava Sciences (SAVA) announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13th international conference on Clinical Trials on Alzheimer’s Disease (CTAD).
What is CTAD?
CTAD is a prestigious annual conference focused on Alzheimer’s . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.